Treatment strategies for clozapine-induced hypotension: a systematic review
Background: Clozapine is the most effective medication for treatment–refractory schizophrenia but is associated with significant adverse drug effects, including hypotension and dizziness, which have a negative impact on quality of life and treatment compliance. Available evidence for the management...
Main Authors: | Timothy David Tanzer, Thomas Brouard, Samuel Dal Pra, Nicola Warren, Michael Barras, Steve Kisely, Emily Brooks, Dan Siskind |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2022-05-01
|
Series: | Therapeutic Advances in Psychopharmacology |
Online Access: | https://doi.org/10.1177/20451253221092931 |
Similar Items
-
Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: study protocol for a pilot randomised controlled trial
by: Karla Mayfield, et al.
Published: (2015-06-01) -
Effects of semaglutide on body weight in clozapine-treated people with schizophrenia and obesity: study protocol for a placebo-controlled, randomised multicentre trial (COaST)
by: Dan Siskind, et al.
Published: (2023-07-01) -
Meeting the mental health needs of low- and middle-income countries: the start of a long journey
by: Steve Kisely, et al.
Published: (2019-11-01) -
Prevalence of frailty in severe mental illness: findings from the UK Biobank
by: Nicola Warren, et al.
Published: (2023-11-01) -
Benefits following community treatment orders have an inverse relationship with rates of use: meta-analysis and meta-regression
by: Steve Kisely, et al.
Published: (2023-05-01)